Physicians' Academy for Cardiovascular Education
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.
Prof. De Boer summarises the interplay between obesity, diabetes and HFpEF, and how the first two conditions may be managed, to minimize their impact on the course of HFpEF.
ESC HF 2018 The second part of the Grand Debate on Drugs or interventions focused on the value of catheter ablation in comparison to drug for treatment of patients with both AF and HF.
ESC 2018 In this debate, it became clear that not all are convinced yet about the use of the new ejection fraction category HFmrEF that was introduced in the latest ESC HF Guidelines in 2016.
ESC HF 2018 A network meta-analysis showed that incremental use of disease-modifying therapies lowers hospitalizations and mortality, which supports guideline recommendations.
ESC HF 2018 In this first debate, John Cleland and Eric Velazquez discussed whether coronary revascularization is superior to optimal medical therapy in stable HF patients.
ESC HF 2018 SwedeHF data show that RASi is associated with reduced morbidity and mortality in HF patients of 80 years and older. Absolute risk reduction is larger than in younger HF patients.
ESC HF 2018 Bucindolol specifically affects a certain polymorphism of the β-1 adrenergic receptor. Treatment of HF patients with this genotype did not prevent AF and AFl in HF patients.
ESC HF 2018 Playing of video games that require rigorous physical exercise yielded significant effects on exercise capacity and well-being in some HF patients.
ESC HF 2018 A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.
ESC HF 2018 In a small, first-in-man, proof-of-concept study, bilateral splanchnic nerve block improved hemodynamics, patient symptoms and physiological markers, for up to 90 minutes
ESC HF 2018 The REPORT-HF registry allows prospective and longitudinal analyses across seven regions in the world. Patients with acute heart failure are not the same everywhere, which affects therapy.